Core Viewpoint - Mirxes has signed a memorandum of understanding with Watson Bio to collaborate in molecular diagnostics and vaccine development, aiming to expand into ASEAN and global markets [1] Group 1: Company Developments - Mirxes' stock rose nearly 8% in early trading, currently up 2.48% at HKD 53.8, with a trading volume of HKD 18.2942 million [1] - The partnership with Watson Bio signifies a strategic collaboration between a leading precision diagnostics company and a top vaccine developer, establishing a solid foundation for an RNA-based preventive and precision medical platform [1] Group 2: Product Approval and Market Impact - In October, Mirxes' core product GASTROClear received approval from the National Medical Products Administration (NMPA) in China, becoming the world's first and only approved molecular diagnostic IVD product for gastric cancer screening [1] - This milestone represents a commercial breakthrough for the company, transitioning from "0 to 1," and is expected to lead to a revaluation of the company's worth [1] - The approval allows Mirxes to enter the vast gastric cancer screening market in China, serving as a significant catalyst for short-term performance [1]

11 月 21 日，以 " 智领健康未来 " 为主题的 2025 华夏大健康产业发展暨康复服务大会在北京召开。作为连续四届引领行业风向的标杆盛会，科技与创新 始终是贯穿全程的灵魂主线，而医疗健康企业在环境、社会及治理方面的表现同样被社会各界关注。 万得 ESG高级分析师 受邀发表了主题演讲，详细介绍了蒲公英指数的构建背景、评估体系及市场表现，强调该指数为医疗健康行业可持续发展提供了重 要参考。 万得首先介绍了 Wind 万得的业务背景： "Wind 是一家专业化的信息服务机构，为金融领域开发了信息检索、数据提取及组合管理等专业工具，是国内外 机构投资者的重要合作伙伴。 " 她特别指出， Wind 构建的独立 ESG 评级体系已广泛应用于政策研究、金融决策和企业实践当中，例如国务院发展研究 中心发布的报告及可持续挂钩债券发行实践。 蒲公英指数亦是 Wind ESG 评级体系的一次创新性应用。该指数由华夏时报大健康研究院与万得联合研发，从医疗健康领域 A 股 495 家公司中精选前 50 家组成 " 蒲公英 50 指数 " ，港股 262 家公司中精选 30 家组成 " 蒲公英 30 指数 " ，每月根据 ESG ...

Core Insights - Mirxes-B (02629) experienced a nearly 8% increase in early trading, currently up 2.48% at 53.8 HKD with a trading volume of 18.29 million HKD [1] Company Developments - On November 18, Mirxes announced a formal memorandum of understanding with Watson Bio (300142.SZ) to collaborate in the fields of molecular diagnostics and vaccine development, aiming to expand in the ASEAN and global markets [1] - This partnership signifies a strategic alignment between a leading precision diagnostics company and a top vaccine development firm, laying a solid foundation for a prevention and precision medicine platform centered around RNA [1] Product Milestones - In October, Mirxes' core product GASTROClear received approval from the National Medical Products Administration (NMPA) in China, becoming the world's first and currently the only approved molecular diagnostic IVD product for gastric cancer screening [1] - This milestone represents a significant commercial breakthrough for the company, transitioning from "0 to 1," and introduces a new valuation logic for the firm [1] - The approval allows the company to officially enter the vast gastric cancer screening market in China, serving as a crucial catalyst for short-term performance [1]

Core Viewpoint - Watson Bio (300142.SZ) has applied for clinical trials of its varicella live attenuated vaccine and has received the acceptance notice from the National Medical Products Administration [1] Group 1: Company Developments - The company, along with its subsidiaries Yunnan Vaccine Laboratory Co., Ltd., Beijing Watson Innovation Biotechnology Co., Ltd., and Yuxi Watson Biotechnology Co., Ltd., is jointly developing the varicella live attenuated vaccine [1] - The vaccine is made using the varicella-zoster virus (VZV) live attenuated strain inoculated in human diploid cells and is produced through a freeze-drying process [1] Group 2: Product Information - The vaccine aims to stimulate the immune system to produce immunity against the varicella-zoster virus, thereby preventing chickenpox [1]

智通财经APP讯，沃森生物(300142.SZ)公告，公司及子公司云南疫苗实验室有限公司、北京沃森创新生 物技术有限公司和玉溪沃森生物技术有限公司共同研发的水痘减毒活疫苗向国家药品监督管理局申请临 床试验，于近日获得《受理通知书》。 ...

沃森生物公告，由公司及子公司共同研发的水痘减毒活疫苗向国家药品监督管理局申请临床试验，近日 获得《受理通知书》。该疫苗采用水痘-带状疱疹病毒减毒株接种人二倍体细胞，经冻干工艺制成，用 于预防水痘。水痘-带状疱疹病毒具有高度传染性，可引发水痘和带状疱疹。目前，国外水痘减毒活疫 苗生产商主要有日本Biken公司、美国默沙东公司和英国葛兰素史克公司，国内有六家企业已获批上市 许可。本疫苗临床试验申请获得受理对公司本年度经营业绩不会产生重大影响。 ...

证券代码：300142 证券简称：沃森生物 公告编号：2025-065 申请人：云南沃森生物技术股份有限公司、云南疫苗实验室有限公司、北京 沃森创新生物技术有限公司、玉溪沃森生物技术有限公司 云南沃森生物技术股份有限公司 关于水痘减毒活疫苗临床试验申请获得受理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 由云南沃森生物技术股份有限公司（以下简称"公司"）及子公司云南疫苗 实验室有限公司、北京沃森创新生物技术有限公司和玉溪沃森生物技术有限公司 共同研发的水痘减毒活疫苗向国家药品监督管理局申请临床试验，于近日获得 《受理通知书》。其主要内容如下： 产品名称：水痘减毒活疫苗 申请事项：境内生产药品注册临床试验 注册分类：预防用生物制品3.3 受理号：CXSL2500991 受理结论：予以受理。 公司研发的本疫苗为采用水痘-带状疱疹病毒（Varicella-zoster virus,VZV）减 毒株接种人二倍体细胞，经冻干工艺制成的减毒活疫苗。接种本疫苗后，可刺激机 体产生抗水痘-带状疱疹病毒的免疫力，用于预防水痘。 VZV 是一种具有高度传染性的疱疹病毒， ...

Core Viewpoint - MIRXES-B has established a strategic partnership with Yunnan Watson Biotechnology to create an RNA-centered prevention and precision medicine platform, enhancing their capabilities in clinical trials, registration, and sales [1] Group 1: Partnership Details - The memorandum of understanding (MOU) between MIRXES and Watson is valid for two years from the signing date [1] - The collaboration aims to leverage the complementary strengths of both companies, creating synergies in their operations [1] Group 2: Technological and Operational Synergies - MIRXES will integrate its advanced RNA diagnostic technology and proprietary Asia-centric disease RNA database with Watson's mRNA vaccine technology [1] - The partnership will utilize MIRXES's production and regulatory capabilities in the ASEAN region, including the first Industry 4.0 nucleic acid testing and reagent production base [1] - The collaboration is expected to enhance both companies' research and commercial deployment capabilities in the field of prevention and precision medicine [1]

Core Viewpoint - MIRXES-B (02629) has seen a significant increase in stock price, rising over 5% in the afternoon trading session, with a current price of 52.55 HKD and a trading volume of 32.73 million HKD. The company has entered into a memorandum of understanding with Yunnan Watson Bio (300142) to establish a strategic partnership focused on RNA-based preventive and precision medicine [1]. Group 1 - The memorandum of understanding is set for a duration of two years from the date of signing [1]. - The collaboration aims to leverage the complementary strengths of both companies, creating synergies in their operations [1]. - The partnership will integrate MIRXES's advanced RNA diagnostic technology and proprietary disease RNA database with Watson's mRNA vaccine technology and robust clinical pipeline [1]. Group 2 - The strategic partnership will encompass joint development, clinical trials, registration, as well as sales and distribution [1]. - The collaboration is expected to establish a comprehensive platform for research and commercial deployment in preventive and precision medicine [1]. - The partnership will also utilize MIRXES's production and regulatory capabilities in the ASEAN region, including the first Industry 4.0 nucleic acid testing and reagent production base [1].

Core Viewpoint - MIRXES-B (02629) has entered into a memorandum of understanding with Yunnan Watson Biotechnology to establish a strategic partnership focused on creating an RNA-centered prevention and precision medicine platform, which includes joint development, clinical trials, registration, and sales and distribution [1] Group 1: Partnership Details - The memorandum of understanding is effective for two years from the date of signing [1] - The collaboration aims to leverage the complementary strengths of both companies to create synergies [1] Group 2: Technological and Operational Synergies - The partnership will combine MIRXES's advanced RNA diagnostic technology and proprietary Asia-centric disease RNA database with Watson's proprietary mRNA vaccine technology and strong clinical pipeline [1] - The collaboration will also utilize MIRXES's production and regulatory capabilities in the ASEAN region, including the first Industry 4.0 nucleic acid testing and reagent production base in the area [1]